aldoxorubicin + avelumab + bevacizumab + cisplatin + cyclophosphamide + nab-paclitaxel

This is an investigational multi-agent combination regimen consisting of six distinct anticancer drugs, each with a unique mechanism of action: - **Aldoxorubicin** is a tumor-targeted prodrug of doxorubicin that binds to serum albumin via an acid-sensitive linker, allowing for selective delivery and release in the acidic tumor microenvironment. It acts as a cytotoxic anthracycline antibiotic, inhibiting topoisomerase II and intercalating DNA to prevent replication and transcription[1][2][3]. - **Avelumab** is a fully human monoclonal antibody targeting programmed death-ligand 1 (PD-L1), functioning as an immune checkpoint inhibitor by blocking PD-L1 interaction with PD-1 receptors on T cells, thereby enhancing antitumor immune responses. - **Bevacizumab** is a recombinant humanized monoclonal antibody that binds vascular endothelial growth factor A (VEGF-A), inhibiting angiogenesis required for tumor growth. - **Cisplatin** is a platinum-based chemotherapeutic agent that forms DNA crosslinks, leading to apoptosis in rapidly dividing cells. - **Cyclophosphamide** is an alkylating agent that interferes with DNA replication and transcription through crosslinking of DNA strands. - **Nab-paclitaxel** (nanoparticle albumin-bound paclitaxel) is an antimicrotubule agent formulated as albumin-bound nanoparticles to enhance delivery; it stabilizes microtubules and inhibits cell division[7][8]. This combination brings together targeted cytotoxics, immunotherapy, antiangiogenic therapy, and classic chemotherapeutics. The regimen would be considered highly experimental; no evidence was found for this exact six-drug combination being approved or widely studied together in clinical trials. Each component has established use or investigation in various solid tumors such as sarcomas, breast cancer, pancreatic cancer, lung cancer, ovarian cancer, head and neck cancers[2][6][7][8].

Other names

doxorubicin albumin-binding prodrug (for aldoxorubicin)Abraxane (for nab-paclitaxel)